Piscataqua Savings Bank Purchases 120 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Piscataqua Savings Bank grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 6,904 shares of the biopharmaceutical company’s stock after buying an additional 120 shares during the quarter. Piscataqua Savings Bank’s holdings in Gilead Sciences were worth $774,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of GILD. YANKCOM Partnership bought a new stake in Gilead Sciences during the 4th quarter valued at $28,000. Newbridge Financial Services Group Inc. bought a new stake in Gilead Sciences during the 4th quarter valued at $33,000. Annis Gardner Whiting Capital Advisors LLC raised its holdings in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 216 shares during the period. Morton Brown Family Wealth LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $35,000. Finally, Whipplewood Advisors LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $35,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of analyst reports. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective on the stock. Bank of America upped their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Royal Bank of Canada upped their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Finally, Piper Sandler upped their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares in the company, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 17,929 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This trade represents a 9.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,929 shares of company stock worth $6,748,980 over the last ninety days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 1.8%

GILD opened at $112.46 on Friday. The stock has a market cap of $139.89 billion, a PE ratio of 303.95, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.69 and a 52 week high of $119.96. The business’s fifty day simple moving average is $105.39 and its 200 day simple moving average is $101.47.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company’s revenue was down .3% on a year-over-year basis. During the same period in the prior year, the company earned ($1.32) EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s payout ratio is currently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.